Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Nano Dimension — Major milestones on schedule

Nano Dimension — Major milestones on schedule

FY16 was a very successful year for Nano Dimension as it delivered the first six DragonFly systems to potential customers for evaluation and raised US$13.8m (gross) to provide finance as it moves into the commercial phase of development. The company appears on track to complete the beta testing phase in mid-2017 and to deliver 50 printers during FY17. We leave our estimates and valuation broadly unchanged.

Analyst avatar placeholder

Written by

Nano Dimension

Major milestones on schedule

FY16 results

Tech hardware & equipment

15 March 2017

Price

NIS4.44

Market cap

NIS221m

Priced at 10 March 2017

NIS3.69:US$

Net cash ($m) at end December 2016

12.4

Shares in issue

49.7m

ADRs in issue

9.9m

Free float

68%

Code

NNDM

Primary exchange

TASE

Secondary exchange

NASDAQ

Share price performance

%

1m

3m

12m

Abs

(9.7)

(6.4)

(13.4)

Rel (local)

(16.5)

(6.6)

(15.5)

52-week high/low

NIS6.5

NIS4.2

Business description

Nano Dimension focuses on the development of advanced 3D printed electronics systems and advanced additive manufacturing. The company’s initial products include a 3D printer for rapid prototyping of multi-layer PCBs and associated nanotechnology conductive and dielectric inks.

Next events

Q117 results

May 2017

Analysts

Anne Margaret Crow

+44 (0)20 3077 57000

Dan Ridsdale

+44 (0)20 3077 5729

FY16 was a very successful year for Nano Dimension as it delivered the first six DragonFly systems to potential customers for evaluation and raised US$13.8m (gross) to provide finance as it moves into the commercial phase of development. The company appears on track to complete the beta testing phase in mid-2017 and to deliver 50 printers during FY17. We leave our estimates and valuation broadly unchanged.

Year
end

Revenue (US$m)

EBITDA*
(US$m)

PBT*
(US$m)

EPADS
($)

DPADS
($)

P/E
(x)

12/15

0.0

(2.4)

(2.1)

(0.39)

0.0

N/A

12/16

0.0

(6.5)

(6.8)

(0.83)

0.0

N/A

12/17e

5.2

(7.7)

(8.8)

(0.89)

0.0

N/A

12/18e

35.7

12.2

11.0

0.93

0.0

7.0

Note: *PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

Major milestones to commercialisation reached

Nano Dimension delivered the first six DragonFly 2020 printers for evaluation during H216, as per its stated target. Management notes that feedback so far has been generally positive, with customers using the printers extensively to create multi-layer PCBs. The company remains on track to deliver a total of around 50 printers during FY17, including around 35 in the commercial roll-out during H217 and to scale this up further during FY18. During FY16 Nano Dimension also successfully lab-tested a proof-of-concept 3D BioPrinter for stem cells using an adapted 3D printer. Management is in the process of establishing a structure for creating a separate entity to pursue the bioprinting opportunity, which will secure its own sources of funding.

First revenues reported during FY16

Nano Dimension generated US$46k revenues during FY16 from leasing DragonFly printers to customers participating in the beta testing programme. Operating losses increased by 57% year-on-year to US$9.0m as the number of employees, most of whom are engaged in R&D, doubled to almost 90. Nano Dimension raised US$12.0m (gross) during H216 through a placing and a further $1.8m (gross) through an over-allotment option, both at US$6.50/ADS. The funds are being used to support the ramp-up in volume, including a c US$1.5m investment in expanding the ink production capability.

Valuation: Significant upside on volume roll-out

Delivery to our estimates and key milestones over the next year would justify significant share price appreciation, with our base case valuation returning a fair value of US$12.97/ADS (unchanged)/NIS9.57/ordinary share (from NIS9.87/share on FX moves). This excludes any additional potential contribution from third-party ink sales or early-stage development programmes. The current share price factors in the risks of setbacks to the commercialisation plan, which is common in early-stage technology companies.

PCB sector roll-out programme on track

In August 2016 Nano Dimension delivered the first DragonFly 2020 system for creating multi-layer printed circuit boards to a leading defence company in Israel for evaluation. Less than a month later, it delivered the first DragonFly to the US. This system is being used by FATHOM, Nano Dimension’s partner, to support demonstrations and product evaluations in the US, especially to potential customers in Silicon Valley and the greater West Coast area. Initial feedback from the first two beta sites was positive, so the initial two shipments were followed by four others by the end of December, in line with management’s stated target. The other four recipients are a US-based Fortune 100 multinational in the technology sector, one of the top 10 largest defence companies globally, Germany-headquartered PHYTEC Messtechnik and a Fortune 500 company that is one of the 10 largest bank holding companies in the US, which will install the printer in its hardware development centre. These beta site customers are keen to bring PCB prototyping in house, thus reducing time to market and ensuring that IP security is not compromised.

The feedback so far has been mainly positive. Customers have been using the printers extensively, in some cases manufacturing five or six PCBs each week with the equipment. The customers have successfully output PCBs with up to 12 layers. The beta testing has uncovered a minor problem with the printer construction, which caused it to leak ink but has now been fixed. In some situations the dielectric ink has cracked when components are soldered to the completed PCB. The formulation of this ink is being adjusted. Management expects to resolve this problem satisfactorily within a few weeks. The resolution of this type of teething problem is to be expected during a beta test phase and highlights why Nano Dimension was keen to have an extended beta test phase with customers that will provide detailed feedback.

Management has confirmed that the roll-out programme is on track, with 50 printers scheduled for delivery during FY17. Management expects to make the first six deliveries for 2017 later this month and to deliver a larger number, also to beta site customers, during Q217. Then around 35 printers will be delivered for the commercial roll-out during H217. The beta site printers will be manufactured in house and manufacturing will be outsourced to Flextronics for the commercial volumes. Deliveries will be scaled up further during FY18. Management has adopted a leasing model for the beta phase rather than a straight sales model. This means that revenues will not be recognised upfront, depressing the top-line P&L, but enables Nano Dimension to select beta site partners on the basis of their ability to provide useful feedback and, ultimately, to become long-term customers.

Nano Dimension is using some of the funds raised to expand the ink production facility so that it can provide the quantity needed once it enters the commercial phase and the volumes of printers being sold ramps up. It has leased another floor in its existing facility in Ness Ziona near Tel Aviv to accommodate ink production. Management expects the new facility, which will cost an estimated $1.5m, to be opened ahead of volume shipments for the commercial roll-out in H217. We model most of the cost of this as falling in FY17.

Technology progress

Although Nano Dimension is highly focused on completing the beta test phase for the PCB printer and software, it has made significant progress in developing 3D print systems for other sectors and the next-generation 3D print system for PCBs. Importantly, it is protecting this IP through patent applications.

Next-generation PCB printing

In January 2017 Nano Dimension announced that it had successfully 3D printed a series of multi-layered rigid PCBs, connected through printed flexible conductive connections. This process provides a solution to traditional production limitations in the electronics industry, enabling PCBs to be bent so that they fit inside curved and complex geometrical products. The company has filed a patent in the US for the flexible conductive and insulating inks that are used in this process, as well as for the printing process itself. Management believes that the company is the first in the world to successfully print multi-layered rigid circuits with flexible connections. The potential market for this solution includes aerospace, defence, wearable equipment and the Internet of Things (IoT).

Later in the same month, Nano Dimension announced that it had successfully 3D printed electrical circuits in which it had inserted embedded electrical components during the printing phase. This technique presents several advantages: it improves the PCB reliability by protecting components from the external environment, it eliminates the soldering process for attaching components to the board and improves connectivity to the components, which is a major source of device failure. The company has filed a patent application in the US to cover this development. Importantly, this represents a step towards printing complete electronic devices where the casing itself supports the electrical components and the connectors joining them, and the shape of the device is not constrained by the need to accommodate a rigid rectangular PCB.

In February 2017 Nano Dimension announced that it had received a budget from the Israel Innovation Authority to finance a project to develop 3D printing of advanced ceramic materials. This project is primarily intended to find a better way of manufacturing aerospace and automotive components. In addition, it potentially gives a route for replacing the insulating material in PCBs with ceramic, thus improving the substrate’s mechanical and thermal characteristics.

New sectors

In May, Nano Dimension successfully lab-tested a proof-of-concept 3D BioPrinter for stem cells using an adapted 3D printer. The trial was conducted in collaboration with Accellta, which provided the suspensions of stem cells. The combination of Accellta’s ability to produce billions of high-quality stem cells per batch and Nano Dimension’s high-precision, high-throughput 3D printing expertise opens the possibility of printing complex biomaterials for use in preclinical drug discovery and testing, cosmetics safety testing, toxicology assays, tissue printing and 'organs on chips'. Nano Dimension has stated that it will form a new entity to address this promising application and raise funds separately for it. In June, the company filed a patent in the US covering the conversion of images of organs from MRI and CT scans into a 3D representation of the biological structure of the tissue and organ, which is then converted into very thin 2D slices for 3D printing. During the FY16 results call to analysts, management noted that it is in the process of forming a separate entity with its own independent sources of finance to commercialise this opportunity. This will focus initially on creating materials with similar functionality to kidney tissue.

Financials

Increased investment in R&D

Nano Dimension reported its first revenues during FY16. These totalled US$46k, broadly in line with our US$36k estimate. These revenues were derived from leasing DragonFly printers to customers participating in the beta testing programme. Operating losses increased by 57% year-on-year to US$9.0m. This is higher than our $7.0m estimate, which assumed that the shift to expensing all R&D costs rather than capitalising a material proportion of them would occur at the year end, rather than at the end of Q3. R&D expenses rose from $2.9m to $4.1m as the number of people engaged in R&D rose from 34 at the end of FY15 to 75 at the end of FY16, as well as an increase in materials expenses reflecting intensifying research and development activities. General and administrative expenses rose from $2.9m to $4.8m, primarily the result of an increase in admin employee numbers from six to 13 and a significant increase in fees for professional services.

Placing to fund commercialisation phase

During H216 Nano Dimension raised US$12.0m (gross) through a placing and a further $1.8m (gross) through an over-allotment option, both at US$6.50/ADS. Cash consumed during the year totalled $10.1m, including $1.1m on tangible assets and $3.0m capitalised R&D (net of amounts recognised in respect of government grants liability), leaving $12.4m net cash at the end of December 2016.

According to management, cash burn is currently around $1m/month. Offsetting this against revenues from printer sales and leasing agreements, and including $1.9m capex, most of which is allocated for the ink production facility, gives an estimated cash outflow during FY17 of $9.8m, leaving $2.6m of cash at the year-end. Our model shows Nano Dimension has sufficient cash to support it through the commercialisation phase of the 3D print system for PCBs, provided it achieves the roll-out rate and pricing assumed in our estimates (see our September note for details). However, it is possible that management may decide to secure additional funding so that it can address the commercial opportunities without being constrained by cash considerations. We note that management intends to establish a separate entity for commercialising 3D print of biological tissues. This will be financed separately from the PCB programme.

Valuation

Our DCF analysis excludes any additional potential contribution from third-party ink sales or early-stage development programmes. The valuation in US$/ADS remains unchanged at US$12.97/ADS. As a result of currency exchange movements, the NIS/ordinary share value has changed from NIS9.87/ordinary share to NIS9.57/ordinary share. Further progress against major milestones, which in the short term are the onset of commercial deliveries and commissioning of the ink production facility, should act as a catalyst to push the share price beyond the current level towards our indicative value.

Exhibit 1: Edison base case DCF sensitivity analysis

US$/ADS

Discount rate

NIS/ordinary share

Discount rate

11.0%

13.0%

15.0%

11.0%

13.0%

15.0%

Term growth

0.0%

14.76

11.94

9.92

0.0%

10.88

8.80

7.32

1.0%

15.55

12.41

10.22

1.0%

11.46

9.15

7.54

2.0%

16.51

12.97

10.57

2.0%

12.17

9.57

7.79

3.0%

17.72

13.65

10.98

3.0%

13.06

10.06

8.09

4.0%

19.27

14.47

11.46

4.0%

14.21

10.67

8.45

Source: Edison Investment Research

Exhibit 2: Financial summary

US$'000

2015

2016

2017e

2018e

Year-end 31 December

IFRS

IFRS

IFRS

IFRS

PROFIT & LOSS

Revenue

 

 

0

46

5,160

35,680

Cost of Sales (including amortisation of capitalised IP)

0

(193)

(2,461)

(12,535)

Gross Profit

0

(147)

2,699

23,145

EBITDA

 

 

(2,437)

(6,465)

(7,667)

12,159

Operating Profit (before amort. and except.)

(2,473)

(6,829)

(8,797)

11,016

Intangible Amortisation

0

0

0

0

Exceptionals

0

(149)

0

0

Other

(3,262)

(2,025)

(2,025)

(2,025)

Operating Profit

(5,735)

(9,003)

(10,822)

8,991

Net Interest

355

38

0

0

Profit Before Tax (norm)

 

 

(2,118)

(6,791)

(8,797)

11,016

Profit Before Tax (FRS 3)

 

 

(5,380)

(8,965)

(10,822)

8,991

Tax

0

0

0

0

Profit After Tax (norm)

(2,118)

(6,791)

(8,797)

9,253*

Profit After Tax (FRS 3)

(5,380)

(8,965)

(10,822)

8,991

Average Number of Shares Outstanding (m)

5.4

8.2

9.9

9.9

EPADS - normalised ($)

 

 

(0.39)

(0.83)

(0.89)

0.93*

EPADS - normalised fully diluted ($)

 

 

(0.39)

(0.83)

(0.89)

0.69*

EPADS - (IFRS) ($)

 

 

(1.00)

(1.10)

(1.09)

0.91

DPADS ($)

0.0

0.0

0.0

0.0

Gross Margin (%)

N/A

N/A

52.3

64.9

EBITDA Margin (%)

N/A

N/A

N/A

34.1

Operating Margin (before GW and except.) (%)

N/A

N/A

N/A

30.9

BALANCE SHEET

Fixed Assets

 

 

4,151

8,903

9,667

8,923

Intangible Assets

2,910

6,787

5,817

4,986

Tangible Assets

1,131

2,006

3,739

3,827

Restricted deposits

110

110

110

110

Current Assets

 

 

9,057

13,323

4,512

21,852

Stocks

0

0

250

1,250

Debtors

264

814

1,564

7,144

Cash

8,665

12,379

2,568

13,328

Restricted deposits

128

130

130

130

Current Liabilities

 

 

(907)

(1,968)

(2,718)

(8,298)

Creditors

(907)

(1,968)

(2,718)

(8,298)

Short-term borrowings

0

0

0

0

Long-Term Liabilities

 

 

(254)

(956)

(1,052)

(526)

Long-term borrowings

0

0

0

0

Liability in respect of government grants

(254)

(956)

(1,052)

(526)

Net Assets

 

 

12,047

19,302

10,409

21,951

CASH FLOW

Operating Cash Flow

 

 

(3,330)

(5,914)

(7,917)

11,159

Net Interest

0

0

0

0

Tax

0

0

0

0

Investment in intangible & tangible assets

(2,344)

(4,167)

(1,894)

(400)

Acquisitions/disposals

0

0

0

0

Financing

14,362

13,525

0

0

Dividends

0

0

0

0

Net Cash Flow

8,688

3,444

(9,811)

10,759

Opening net debt/(cash)

 

 

(207)

(8,665)

(12,379)

(2,568)

HP finance leases initiated

0

0

0

0

Other

(230)

270

0

0

Closing net debt/(cash)

 

 

(8,665)

(12,379)

(2,568)

(13,328)

Source: Company accounts, Edison Investment Research. Note: *Normalised for tax.

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively “the Scheme”, “TASE”, “Participant” and/or “Participants”). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively “Edison Israel” and “Edison”), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter “the Agreement”), regarding the Participants and according to the Scheme (hereinafter “the Analysis” or “Analyses”). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter “the ISA”) website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of $35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities’ regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2017. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205, 95 Pitt Street,

Sydney , NSW 2000,

Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205, 95 Pitt Street,

Sydney , NSW 2000,

Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting. Edison is authorised and regulated by the Financial Conduct Authority. Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Service Providers Register (FSP number 247505) and is registered to provide wholesale and/or generic financial adviser services only. Edison Investment Research Inc (Edison US) is the US subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited [4794244]. www.edisongroup.com

EDISON ISRAEL DISCLAIMER

Disclosure regarding the scheme to enhance the awareness of investors to public companies in the technology and biomed sectors that are listed on the Tel Aviv Stock Exchange and participate in the scheme (hereinafter respectively “the Scheme”, “TASE”, “Participant” and/or “Participants”). Edison Investment Research (Israel) Ltd, the Israeli subsidiary of Edison Investment Research Ltd (hereinafter respectively “Edison Israel” and “Edison”), has entered into an agreement with the TASE for the purpose of providing research analysis (hereinafter “the Agreement”), regarding the Participants and according to the Scheme (hereinafter “the Analysis” or “Analyses”). The Analysis will be distributed and published on the TASE website (Maya), Israel Security Authority (hereinafter “the ISA”) website (Magna), and through various other distribution channels. The Analysis for each participant will be published at least four times a year, after publication of quarterly or annual financial reports, and shall be updated as necessary after publication of an immediate report with respect to the occurrence of a material event regarding a Participant. As set forth in the Agreement, Edison Israel is entitled to fees for providing its investment research services. The fees shall be paid by the Participants directly to the TASE, and TASE shall pay the fees directly to Edison. Subject to the terms and principals of the Agreement, the Annual fees that Edison Israel shall be entitled to for each Participant shall be in the range of $35,000-50,000. As set forth in the Agreement and subject to its terms, the Analyses shall include a description of the Participant and its business activities, which shall inter alia relate to matters such as: shareholders; management; products; relevant intellectual property; the business environment in which the Participant operates; the Participant's standing in such an environment including current and forecasted trends; a description of past and current financial positions of the Participant; and a forecast regarding future developments in and of such a position and any other matter which in the professional view of the Edison (as defined below) should be addressed in a research report (of the nature published) and which may affect the decision of a reasonable investor contemplating an investment in the Participant's securities. To the extent it is relevant, the Analysis shall include a schedule of scientific analysis of an expert in the field of life sciences. An "equity research abstract" shall accompany each Equity Research Report, describing the main points addressed. The full scope reports and reports where the investment case has materially changed will include a thorough analysis and discussion. Short update notes, where the investment case has not materially changed, will include a summary valuation discussion. The Agreement with TASE regarding the participation of Edison in the scheme for the research analysis of public companies does not and shall not constitute an approval or consent on the part of TASE or the ISA or any other exchange on which securities of the Company are listed, or any other securities’ regulatory authority which regulates the issuance of securities by the Company to the content of the Report or to the recommendation contained therein. A summary of this report is also published in the Hebrew language. In the event of any contradiction, inconsistency, discrepancy, ambiguity or variance between the English Report and the Hebrew summary of said Report, the English version shall prevail; and a note to this effect shall appear in any Hebrew summary of a Report. Edison is regulated by the Financial Conduct Authority. According to Article 12.3.2, Chapter 12 of the Conduct of Business Sourcebook, Edison, which produces or disseminates non-independent research, must ensure that it: 1) is clearly identified as a marketing communication; and 2) contains a clear and prominent statement that (or, in the case of an oral recommendation, to the effect that) it: a) has not been prepared in accordance with legal requirements designed to promote the independence of investment research; and b) is not subject to any prohibition on dealing ahead of the dissemination of investment research. The financial promotion rules apply to non-independent research as though it were a marketing communication.

EDISON INVESTMENT RESEARCH DISCLAIMER

Copyright 2017 Edison Investment Research Limited. All rights reserved. This report has been prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investors. This research is issued in Australia by Edison Aus and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act. The Investment Research is distributed in the United States by Edison US to major US institutional investors only. Edison US is registered as an investment adviser with the Securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information about companies in which we believe our readers may be interested and this information reflects our sincere opinions. The information that we provide or that is derived from our website is not intended to be, and should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison’s solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are “wholesale clients” for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. This document is provided for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. Edison has a restrictive policy relating to personal dealing. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report. Edison or its affiliates may perform services or solicit business from any of the companies mentioned in this report. The value of securities mentioned in this report can fall as well as rise and are subject to large and sudden swings. In addition it may be difficult or not possible to buy, sell or obtain accurate information about the value of securities mentioned in this report. Past performance is not necessarily a guide to future performance. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a “personalised service” and, to the extent that it contains any financial advice, is intended only as a “class service” provided by Edison within the meaning of the FAA (ie without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision. To the maximum extent permitted by law, Edison, its affiliates and contractors, and their respective directors, officers and employees will not be liable for any loss or damage arising as a result of reliance being placed on any of the information contained in this report and do not guarantee the returns on investments in the products discussed in this publication. FTSE International Limited (“FTSE”) © FTSE 2017. “FTSE®” is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE’s express written consent.

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205, 95 Pitt Street,

Sydney , NSW 2000,

Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Frankfurt +49 (0)69 78 8076 960

Schumannstrasse 34b

60325 Frankfurt

Germany

London +44 (0)20 3077 5700

280 High Holborn

London, WC1V 7EE

United Kingdom

New York +1 646 653 7026

245 Park Avenue, 39th Floor

10167, New York

US

Sydney +61 (0)2 8249 8342

Level 12, Office 1205, 95 Pitt Street,

Sydney , NSW 2000,

Australia

Tel Aviv +44 (0)20 3734 1007
Medinat Hayehudim 60,

Herzilya Pituach, 46766

Israel

Blancco Technology Group — Growth from (data) destruction

As the leading provider of data erasure software for the enterprise market, Blancco is well positioned to exploit the growing requirement for secure data erasure. With major investment in sales and support complete and regulatory changes in its favour, Blancco is in a good position to drive adoption of its software via its direct sales and partner channels. The company’s patented technology and numerous certifications create a strong barrier to entry.

Continue Reading

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free